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I. Introduction 
 
Rare diseases (RDs), also called orphan diseases are those which affect only a very small portion 
of the population and the majority of them (80%) are genetic. According to the latest international 
agreement, the prevalence threshold for RD not more than 5 affected persons per 10,000 (European 
Parliament and of the Council of 16 December 1999). Up to date more than 6000 RDs are 
characterised by a broad diversity of symptoms. Many of them are characterized by mental 
retardation and affects 50-70% of children and even today around 30% of the affected patients will 
die under the age of five. The common symptoms can mask the basic rare diseases which can lead 
to misdiagnosis and delays treatment. In 1997 the Orphanet database was created which aim is to 
provide information about rare disease to clinicians, patients in order to contribute to the successful 
diagnosis and to better treatment. RDs were registered with one offered name and as many 
synonyms with an ORPHA number (www.orpha.net). As the result of this it makes even more 
difficult to even guess the exact number of rare diseases. Majority of RDs are monogenic, however 
due to the „umbrella terms” used for disease groups with overlapping phenotype there are 
numerous complex diseases that are caused by few to hundreds of genes (nephrosis, schizophrenia, 
ECD, COPD, etc.). Due to the technical limitations and the wide spectrum of the phenotypes the 
diagnosis of the rare disease cases are very complicated and the vast majority of them remains 
unsolved. 
Up to recently the clinical genetic diagnosis of complex diseases were only partially solved. Sanger 
sequencing of hundreds of genes is not feasible in the diagnostics due to the enormous manual 
work and costs of the analysis. This challenge was partially handled by Orphanet where the most 
frequent genes or specific mutations causing various diseases were analysed in specific expert 
centres. Our genetic diagnostic laboratory is an expert centre of several RDs, including monogenic 
and complex diseases. Among others, we use diagnostic methods to analyse the most frequent X 
linked type (COL4A5 gene) Alport syndrome and X linked type ECD (EDA gene). In many cases 
the traditional (linkage analysis, high resolution melting analysis, Sanger sequencing based) 
methods investigating only the most frequent genes did not revealed the genetic cause of the 
disease. 
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Recently with the advancement of high-throughput massively parallel sequencing technologies 
(New Generation Sequencing, NGS) it became possible to sequence more genes and more samples 
at the same time. Since we had numerous unsolved cases of complex disease patients we wanted 
to establish and test the feasibility of NGS. In my thesis I chose to work with Alport syndrome and 
ectodermal dysplasia in order to improve their current molecular diagnostic approach in our 
laboratory, thus my thesis has two parts: 
I.1. Alport related disorders 
 
Familiar benign haematuria (FBH) and Alport syndrome (AS) are familial haematuria diseases 
which in case of AS regularly escalate to chronic kidney disease (CKD) stage 5 (formerly referred 
as end stage renal disease). AS patients usually have sensorineural high-tone deafness and ocular 
abnormalities affecting the lens and fundus 1,2. Today more focus has been placed on treating 
patients early to prevent or delay future end stage kidney damage. Although, the pathogenesis of 
CKD is multifactorial, some of the suggested therapeutic interventions (anti-hypertensive therapy, 
glycaemic control, anti-proteinuric therapy, renoprotection, and life style management such as 
restricted protein intake, cessation of cigarette smoking and chronic analgesic-abuse) are 
encouraging. These preventive steps the more earlier are implemented the more efficient they are3–
5. There has been an old and ongoing dispute to differentiate between AS and FBH based on the 
wide spectra of observed clinical symptoms, microscopic analysis of renal biopsy, immunological 
examination and family history 6. The first observed clinical signs are postponed by the fact that in 
the intrauterine life our glomerular basal membrane does not contain COL4A3-A4-A5, but COL4A1 
and COL4A2. First symptom of AS is haematuria which appears usually 10-15% of cases in the 
first year of life, while the majority of patients show symptoms only around 5-7 years of age 7. 
Because of this late manifestation and similarity between early symptoms of AS and FBH neither 
clinical nor histological methods are appropriate for early diagnosis. However, the correct 
genotyping can give an informed clue for the expected progression of the disease, aid the 
determination of mode of inheritance useful to the family members showing yet no symptoms, and 
most crucially is unavoidable for kidney donor selection 7,8. In order to determine the mode of 
inheritance of AS and/or FBH a pathogenic mutation(s) in the COL4A5 gene present on X 
chromosome or mutations in either the COL4A3 or COL4A4 genes on chromosome 2 should be 
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found 9. The most common form of AS, with approximately 4 in every 5 cases, is inherited in an 
X-linked fashion. X linked carrier females usually show variable intermediate phenotype. Due to 
imbalances in random X inactivation the phenotype can vary even between family members. In 
case of FBH, the mode of inheritance is autosomal dominant, and this disease is caused by a single 
heterozygous mutation either in COL4A3 or in COL4A4 genes 10. If there are two mutations either 
in COL4A3 or COL4A4 genes,—a more severe— form of AS develops. Because of this FBH can 
be viewed as the carrier state of AS. There are very few reports in the literature, the vast majority 
of which from the pre-next generation sequencing (NGS) era where autosomal dominant form of 
AS reported, and only one mutation was found in either the COL4A3 or COL4A4 gene. Up to now 
it is not clear whether this form of AS may only be the result of prior technical limitations or it is 
real, which can be solved only with sequence-based analysis of larger data set and with the 
introduction of a new technology 11.  
In my thesis I focus on the improvement of genetic diagnosis of type IV collagenopathies, AS and 
FBH 12. Sequential (one by one) genetic testing for mutations in COL4A3-A4-A5 genes has become 
an integral part of the clinical evaluation. In our previous study on type IV collagenopathies we 
detected large number (more than a dozen) of non-synonymous variants in each individual in these 
3 genes, therefore the distinction between causative mutations and benign variants is crucial 13. 
Since all three genes are large (contains 52, 48 and 51 exons, respectively) the use of conventional 
Sanger sequencing is time-consuming, expensive and can suffer from some technical limitation 
(such as failing to detect insertion/deletion with certain sizes in a heterozygote subject). One way 
to overcome these problems is to sequence all three genes simultaneously using NGS-targeted 
sequencing 14. We present a new, efficient, amplicon based NGS protocol for simultaneous analysis 
of the coding regions (all the exons and flanking intronic sequences) of the COL4A3, A4 and A5 
genes since a previously published NGS-based approach failed to detect mutations in 45% of their 
cases 11. Both mutations and polymorphisms in the 3 investigated COL4A genes are thought to be 
highly population-specific due to the lack of selection pressure in case of the polymorphisms and 
low selection pressure in case of TBMN. Thus, in order to further aid the classification of COL4A3-
A4-A5 genetic variations, we present COL4A3-A4-A5 polymorphisms of 66 unrelated Hungarian 
non AS/TBMN patients’ data obtained by NGS. In addition we set the task of identifying the 
genetic causes of 17 Hungarian AS/TBMN independent cases, analysing 17 AS/TBMN patients 
using our panel and Sanger validation of 55 additional family members. 
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I.2. Ectodermal dysplasia disorders 
 
Ectodermal dysplasias (ECD) are inherited disorders characterized by abnormal 
morphogenesis of ectoderm 15. Ectoderm is one of the three primary germ layers during the 
development of early embryo. Ectodermal dysplasias are hereditary diseases which represents a 
large group of conditions in which two or more ectodermally-derived tissues fail to develop. There 
are more than 150 types of Ectodermal dysplasias described so far, with an incidence of 7/10000 
45. Based on the inheritance pattern within family one can differentiate between autosomal 
recessive (AR), autosomal dominant (AD), X-linked recessive (XR) and X-linked dominant (XD) 
inherited forms 16. The number of the genes and the different phenotypes make difficult the 
diagnosis for the clinicians and for the geneticist. The most common form of ECD is the X-linked 
Hypohidrotic ectodermal dysplasia (XL-HED) characterized by hypotrichosis, hypohidrosis, 
hypodontia. The prevalence of XL-HED is 1/5000-10000 in newborns 17.  
 
 
Figure 1. Derivatives of ectoderm 
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Based on the different clinical symptoms it is not easy to assign the exact type of ECD in the 
majority of the cases. The phenotypes are not always recognizable in newborn babies but usually 
identifiable in early childhood. The following tissues are affected in ECD: 
 
Hair: the hair is absent on the scalp, sparse and light with abnormal texture. The hair may 
also be fragile and curly. The hair is usually dry because of the absence of the oil glands. The 
eyebrows and eyelashes or the other body hair may absent or sparse. Any of the hair defects could 
manifest at birth, while others are not until later age. 
Nails: nail usually poorly developed on the fingers and on the toes. Usually thick, sharp, 
stands out, fragile and brittle. Additionally, the nails grow more slowly and become easier infected 
by fungus or yeast. 
Teeth: may be missing or reduced in number. Teeth are widely spaced and tapered/peg 
shaped. If the teeth are missing than the jawbones in which were embedded do not develop well, 
that cause the „old age appearance” of the face. 
Sweat glands: characterized by missing and scattered. Due to the functional problems the 
body is unable to maintain the normal body temperature. As a result the extreme high body 
temperature is usual that is why the patients unable to tolerate the high outside temperature. The 
recurrent fever periods are the first symptoms which help the diagnosis the ECD in early childhood 
(hypohidrotic and anhidrotic form of ECD). 
Further symptoms: light skin contains red and brown pigments. The skin on the fingers and on 
the toes is particularly thick. The abnormal development of the ear can lead to hearing loss/hearing 
impairment. The presence of cleft palate/lip is usual. The lack of the secretion in glands (in the 
mouth and nose) can result throat infections which can make breathing relatively difficult.  
We distinguish four main symptoms of ECD based on their clinical features 18.  
 
ECD1: Trichodysplasia (hair dysplasia) 
ECD2: Dental dysplasia (teeth dysplasia) 
ECD3: Onychodysplasia (nail dysplasia) 
ECD4: Dyshidrosis (sweat gland dysplasia).  
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Based on the combination of the previously mentioned 4 groups of symptoms the following clinical 
syndromes can occur: 
 
 Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome) 
 Ankyloblepharon-ectodermal defects-cleft lip and palate syndrome (AEC syndrome) 
 Cartilage-hair hypoplasia syndrome 
 Cleft lip/palate-ectodermal dysplasia syndrome 
 Clouston syndrome 
 Congenital hypotrichosis with juvenile macular dystrophy 
 EEC Syndrome 
 Ectodermal dysplasia, pure hair and nail type 
 Ectodermal dysplasia, skin fragility syndrome 
 Ectodermal dysplasia, with ectrodactyly and macular dystrophy 
 Ectrodactyly-ectodermal dysplasia-cleft lip/palate syndrome (EEC syndrome) 
 Focal dermal hypoplasia syndrome 
 Hypohidrotic ectodermal dysplasia 
 Hypohidrotic ectodermal dysplasia, with immune deficiency 
 Hypohidrotic ectodermal dysplasia, with immune deficiency, osteopetrosis and 
lymphoedema 
 Incontinentia pigmenti 
 Limb-mammary syndrome 
 Naegeli syndrome 
 Rapp-Hodgkin syndrome 
 Rothmund-Thomson syndrome 
 
Around 141 gene were linked to ECD. Due to the number of the genes the traditional molecular 
genetic methods when analysis carried out gene by gene is not feasible. Because of this I used a 
different approach called clinical exom sequencing (CES) which allows simultaneous investigation 
of all known 141 ECD genes. The exome sequencing is a targeted sequencing approach which is 
restricted to the protein-coding regions of the genome (exom).  
 10 
 
I.3. Aims 
 
In my thesis addressed the following problems: 
 
- Identifying the causative genetic alterations in 14 nephropathy families and 3 nephropathy 
individuals  
- Try to give a better description to the controversial inheritance (AR, AD) mode of Alport 
and TBMN. 
- Identifying the causative genetic alterations in three families with different ECD 
syndromes. 
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II. Patients 
 
II.1. Alport related disorders 
 
Our Hungarian cohort consisted of 3 individuals (I1-I3, where family members were not available 
for either clinical or genetic analysis) and 14 COL IV nephropathy families (F1-F14) where clinical 
data and inheritance of clinical symptoms supported Alport/FBH diagnosis while other possible 
clinical causes were excluded. All volunteer family members underwent urinalysis and renal 
function evaluation. Kidney biopsy was not performed on all proband. All available clinical and 
pathological information is summarized in Table 1. After obtaining written informed consent 
peripheral blood samples were collected from both the affected and unaffected members of the 
families. We used anonymised DNA samples from our licensed biobank for the 66 Hungarian non 
AS/FBH control samples. Criteria for FBH: mild persistent haematuria (25-30 RBC/HPF), mild 
(0.5-1.0 g/day) or no proteinuria, first appearance after 10 years of age. Criteria for Alport: 
persistent haematuria (>30, 50-100 RBC/HPF), persistent proteinuria (0.5-5.0 g/day).
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Family Individuals Age Hematuria Proteinuria Renal function Biopsy, 
histology 
hearing  
F1 I/2  36 
yrs 
microhematuria  none normal none normal 
 II/2  3 
yrs 
persistent 
hematuria 
 none normal At age 3 could 
not 
discriminate 
between AS or 
TBMN 
normal 
F2 I/1  58 
yrs 
none   none normal not performed  normal 
 II/2 31 
yrs 
microhematuria yes normal At age of 31 
TBMN was 
suggested 
normal 
F3 I/2 53 
yrs 
hematuria none normal At age 7: 
suggested 
TBMN 
ND 
 II/1 32 
yrs 
hematuria yes on dialysis At age 17: 
suggested 
TBMN 
ND 
 II/2 30 
yrs 
hematuria 0.5 g/day eGFR 90 (CKD Stage 
1), had transplantation 
and now on dialysis 
not performed ND 
F4 I/1 38 
yrs 
microhematuria no normal level of se-
creatinine 
not performed mild 
right-
side and 
moderate 
left-side 
hipacusis 
 II/1 15 
yrs 
ND ND on dialysis since age 
of 15 
not performed bilateral 
mild 
hipacusis 
 II/2 13 
yrs 
hematuria 5 g/day at 
age of 13 
 At age of 18 
diffusely thin 
GBM, basket 
weaving in 
several loops, 
α3 chain was 
entirely 
absent, α5 
chain 
exhibited very 
focal 
expression 
ND 
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 II/3 16 
yrs 
microhematuria ND normal ND normal 
at age of 
29 
F5 I/2 86 
yrs 
hematuria ND ND ND ND 
 II/3 61 
yrs 
hematuria ND ND ND ND 
 II/4  hematuria ND ND ND ND 
 III/2 30 
yrs 
ND ND kidney transplantation 
at age of 31 
ND ND 
 IV/1 17 
yrs 
hematuria yes no kidney 
transplantation at age 
of 25 
ND normal 
at age of 
25 
 IV/2 and 
IV/3 twins 
16 
yrs 
ND ND both had kidney 
transplantation at age 
of 16 
ND ND 
F6 II/1 died at 
age 13 
13 
yrs 
ND ND ND ND ND 
 II/5 21 
yrs 
hematuria yes ND At age 11; not 
conclusive 
ND 
F7 I/1 80  
yrs 
none none se-creatinine normal not performed ND 
 I/2 49 
yrs 
10-12 
dysmorphic 
RBC/hpf 
yes se-creatinine normal At age of 49 
diffusely thin 
GBM, 
glomerular 
scars 
moderate 
bilateral 
hearing 
loss 
 II/2 60 
yrs 
10-15 
dysmorphic 
RBC/hpf 
yes se-creatinine normal not performed ND 
 II/4 62 
yrs 
10-15 
dysmorphic 
RBC/hpf 
none ND not performed ND 
 III/1 46 
yrs 
8-10 
dysmorphic 
RBC/hpf 
none se-creatinine normal At age of 46 
diffusely thin 
GBM 
bilateral 
hearing 
loss 
 III/3 42 
yrs 
hematuria yes ND not performed ND 
 III/4 40 
yrs 
hematuria ND ND ND ND 
 III/6 47 
yrs 
30-35 
dysmorphic 
RBC/hpf  
1.5 g/day se-creatinine normal At age of 47 
diffusely thin 
GBM, doubled 
in some loops 
bilateral 
hearing 
loss 
 III/8 44 
yrs 
hematuria ND ND not performed ND 
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 III/9 42 
yrs 
25-30 
dysmorphic 
RBC/hpf 
0.8 g/day se-creatinine normal At age of 42 
diffusely thin 
GBM 
moderate 
bilateral 
hearing 
loss 
 IV/1 17 
yrs 
8-10 
dysmorphic 
RBC/hpf 
3 g/day  se-creatinine normal At age of 17 
diffusely thin 
GBM, with 
splitting in 
some loops 
moderate 
bilateral 
hearing 
loss 
 IV/2 24 
yrs 
8-10 
dysmorphic 
RBC/hpf 
3 g/day se-creatinine normal At age of 24 
diffusely thin 
GBM, with 
splitting in 
some loops 
bilateral 
hearing 
loss 
 IV/3 36 
yrs 
hematuria ND ND not performed normal 
 IV/7 15 
yrs 
50-60 
dysmorphic 
RBC/hpf 
0.8 g/day se-creatinine normal At age of 15 
diffusely thin 
GBM 
moderate 
unilateral 
hearing 
loss 
 V/1 4 
yrs 
persistent 
hematuria 
ND ND not performed normal 
at age of 
4 
F8 I/1 38 
yrs 
hematuria ND ND not performed normal 
 II/1 5 
yrs 
hematuria ND ND not performed normal 
 II/2 12 
yrs 
100 RBC/hpf ND ND not performed normal 
F9 I/1 71 
yrs 
hematuria ND ND not performed ND 
 II/2 45 
yrs 
hematuria ND ND At age of 32 
could not 
confirm either 
AS or TBMN 
ND 
 III/1 16 
yrs 
hematuria ND ND At age of 3 
TBMN was 
suggested 
ND 
F10 II/1 65 
yrs 
hematuria ND ND not performed ND 
 II/2 67 
yrs 
hematuria ND ND not performed ND 
 III/2 44  
yrs 
hematuria ND ND not performed ND 
 IV/1 12  
yrs 
hematuria ND ND not performed mild 
hipacusis 
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Table 1. Clinical and pathological details of the investigated Hungarian AS/FBH families. 
 
F11 I/1 50 
yrs 
30 RBC/hpf ND ND not performed ND 
 II/1 24 
yrs 
30 RBC/hpf yes ND At age of 24 
secondary 
FSGS, likely 
TBMN but 
could not 
exclude AS 
normal 
 II/2 15  
yrs 
30 RBC/hpf yes decreasing eGFR ND ND 
F12 II/1 69 
yrs 
hematuria none ND not performed normal 
 II/3 71 
yrs 
hematuria none ND not performed normal 
 II/5 68  
yrs 
hematuria none ND not performed normal 
 III/3 37  
yrs 
hematuria none ND At age of 42 
TBMN was 
suggested 
normal 
 III/6 42  
yrs 
hematuria none ND not performed normal 
 III/7 35  
yrs 
hematuria none ND not performed normal 
 III/8 39  
yrs 
hematuria none ND not performed normal 
F13 I/1 38 
yrs 
hematuria no ND ND normal 
 II/2 6 
yrs 
hematuria no ND ND normal 
F14 I/2 35 
yrs 
microhematuria no ND not performed ND 
 II/1 2 
yrs 
microhematuria 
at age of 3 
no ND not performed ND 
 Individuals Age Hematuria Proteinuria Renal function Biopsy, 
histology 
hearing  
 I1  35 
yrs 
hematuria yes ND not performed ND 
 I2  38 
yrs 
microhematuria 0.8 g/day ND not performed ND 
 I3   1 
yr 
hematuria none ND not performed ND 
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RBC – red blood cell ; eGFR – estimated glomerular filter rate; CKD – chronic kidney disease; 
ND – no data; hpf – (microscopic) high power field; FSGS – focal segmental glomerulosclerosis, 
GBM – Glomerular basement membrane, AS – Alport syndrome, FBH –Familiar Benign 
Hematuria. There was no data on eye sight problems in the patients. 
 
II.2. Ectodermal dysplasia patients 
 
II.2.1. Family I. 
The following table contains the clinical symptoms of the investigated family I. members. 
Family member Code Clinical symptoms 
Proband ECD2 
frequent periods of high fever 
hypohidrosis 
peg-shaped teeth 
lack of eyebrows/lashes/hair 
Mother ECD7 
fever periods 
hypodontia  
body hair in various part of the body 
Father ECD6 unaffected 
Grandmother ECD4 
fever periods 
hypodontia  
body hair in various part of the body 
Sister ECD8 unaffected 
Brother ECD3 unaffected 
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Figure 2. Family tree of the Family I. 
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Figure 3. The affected man’s (ECD2) head 
 
 
 
Figure 4. Leg of the mother (ECD7). The right leg is hairy but the left is hairless. 
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II.2.2. Family II. 
 
The following table contains the clinical symptoms of the investigated family II. members. 
Family member Code Clinical symptoms 
Proband ECD14 
Hipohydrosis 
Sparse hair 
malformed-, peg-shaped teeth 
syndactyly 
double nipples 
Mother ECD19 
tooth agenesis, sharp tooth 
sparse hair 
reduced sweating ability 
Father ECD20 unaffected 
Sister ECD21 
Tooth agenesis, sharp tooth 
sparse hair 
reduced sweating ability 
Nephew ECD22 Tooth agenesis 
 
 Hypohidrosis, sparse hair Hypodontia 
Figure 5. Family tree of the Family II. 
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Figure 6. The symptoms of the affected boy (ECD14). a, b: parse hair; c: lack of eyelashes and 
eyebrows; d: syndactily; e: hypodontia-only two permanent teeth; f: double nipple. 
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II.2.3. Family III. 
The following table contains the clinical symptoms of the investigated family II. members. 
 
Family member Code Clinical symptoms 
Proband ECD29 
absent hair, eyebrows, eyelashes, 
severely dystrophic nails syndactyly 
Mother ECD31 unaffected 
Father ECD30 unaffected 
 
 
 
Figure 7: Family tree of the affected boy (ECD29) 
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Figure 8. The affected boy (ECD29) 
 
Based on the clinical symptoms we had chosen one affected member (proband) from every 
family to be first investigated with NGS. 
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III. Material and Methods 
 
In accordance with Hungarian regulations written informed consent was obtained from each patient 
in the framework of a genetic counselling session. The study protocol adhered to the tenets of the 
Declaration of Helsinki and was approved by the regional ethical committee (Ethical board of 
University of Szeged). 
The genomic DNA from peripheral blood leukocytes was isolated by salting out procedure. 
 
III.1. Targeted resequencing of Alport related genes 
 
Our AS/FBH panel consisting of all the three COL4A3-4-5 genes which was designed in-
house using the Ion AmpliSeq™ Designer version 4.2.1 from Life Technologies. Gene enrichment 
was performed by the AmpliSeq amplicon based system. Sample enrichment was performed by 
the Ion AmpliSeq(TM) Library Kit, Life Technologies. The samples were barcoded and sequenced 
on IonTorrent 316 chip. We aimed for at least 25 times coverage (more than 90% of the target were 
covered at least 100 times and more than 95% of the target were covered at least 50 times). 
Bioinformatical analysis was performed by CLC Bio, Torrent Suite 4.2 and Illumina VariantStudio 
softwares. 
III.2. Clinical exom sequencing of ectodermal dysplasia related genes 
 
To analyse the samples we used the Illumina TruSight One Sequencing Panel. The TruSight One 
sequencing panel provides comprehensive coverage of 4813 clinically relevant genes selected from 
the Online Mendelian Inheritance in Man (OMIM), Human Gene Mutation Database Professional 
(HGMD) and GeneTests databases.  
We followed the user manual of TruSight One kit for the library preparation and sequencing. We 
used 50ng gDNA.  The cumulative target region: 12Mb; the minimum coverage of the target region 
was >20x (no. target exons: 62000; probe size: 80mer; 150bp pair-end reads). The samples were 
sequenced on Illumina MiSeq platform. 
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Alignment and variant calling was performed by BWA + GATK HaplotypeCaller. We used in 
house algorithms for detection of large structural rearrangements and copy number variations 
(CNV). We used VariantStudio for variant annotation, filtration and classification. 
III.3. Variant confirmation workflow 
 
To confirm and evaluate the putative disease causing genetic variations we designed 
primers by Primer3Plus software and executed PCR amplification for all members of our cohort 
19. PCR products were purified using High Pure PCR Product Purification Kit, (Roche) and 
sequenced on Applied Biosystems HITACHI 3500 Genetic Analyser. For visualization of the 
Sanger sequencing we used FinchTV (Geospiza Inc.). 
To visualize the results of NGS we used IGV 2.3 and Illumina Variant Studio 2.2 versions. 
We compared the results with the following public databases: HGMD 20, LOVD 21, 
1000Genomes.org 22, Alport database (ARUP) 23. All the previously unpublished mutation were 
submitted in LOVD database (http://grenada.lumc.nl/) and can be found in ClinVar database as 
well (http://www.ncbi.nlm.nih.gov/clinvar/). 
 
See our variant classification criteria system in supplement 1.  
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IV. Results 
 
 
AS/FBH Multiplex AmpliSeq panel design for simultaneous analysis of Col4A3-A4 and A5 genes. 
Our AS/FBH AmpliSeq panel is designed for standard (not formalin-fixed paraffin embedded 
(FFPE)) DNA, with amplicon size range of 125-225bp. The designed 197 amplicons were 
organized into two (99 and 98 amplicons, respectively) pools. Our targets (all three genes coding 
exonic regions with 15 bp padding) were as follows: 5,013 bp COL4A3 (covering 96.361% of the 
planned region), 5,073 bp COL4A4 (97.02% covering) and 5,383 bp COL4A5 (98.86% covering). 
The overall target size was 29.4 kb with an average coverage of 97.63%. 
 
 
 
IV.1. Analysis of Hungarian non AS/FBH cohort 
 
By analysing the 66 Hungarian non AS/FBH controls we wished to identify population-
specific polymorphisms in order to help distinguish polymorphisms from causative mutations in 
our AS/FBH cohort. We have found 21 unique synonymous exonic and intronic genetic variances 
within the investigated COL4A3, COL4A4 and COL4A5 genes. We identified 11 genetic variants 
in COL4A3, 9 variants in COL4A4 and only one in COL4A5 gene. All of them were already 
published elsewhere (Table 2). 
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Gene Variant MAF Consequence Published 
in 
Family (F) or Individual (I) 
COL4A3 c.127G>C 0.153 p.Gly43Arg 24 F1 (M),F5 (M),F6 (M),F10 
(M),F13 (M) 
 c.1721C>T 0.121 p.Pro574Leu 25 F1 (M),F5 (M),F2 (F),F4 (F),F8 
(F), F10 (M),F11 (F),F12 (F),F13 
(M),F14 (F),I1(M), I2 (M), I4,F1 
(M), F5 (M) 
 c.3325C>T 0.024 p.Pro1109Ser 26 F4 (F) 
 c.547-9A>C 0.024 IV rs55667591 F3 (F), F4(F) 
 c.3807C>A 0.040 p.Asp1269Glu 25 F2 (F), F6 (M) 
 c.976G>T 0.226 p.Asp326Tyr 27 F3 (F), F6 (M), I3 (M), F7 (M), 
F13 (M), F11 (F), F8 (F) 
 c. 2384-5T>C 0.113 IV 28 F10 (M), F7 (M) 
 c.485A>G 0.798 p.Glu162Gly 29 F3 (F), I1 (F), F6 (M), F7 (M), F11 
(F), F9 (F), F1 (M), F2 (F), F10 
(M), F4 (F), I2 (M), F5 (M), F12 
(F), F12 (F), I3 (M), F8 (F), F13 
(M), F13 (F) 
 c. 
144+12C>A 
0.339 IV 29 F8 (F) F3 (F), F10 (M), I1 (F), I2 
(M), F6 (M), I3 (M), F13 (M), F11 
(F), F9 (F) 
 c.422T>C 0.798 p.Leu141Pro 26 F1 (M), F2 (F), F10 (M), F4 (F), I2 
(M), F5 (M), F12 (F), F12 (F), I3 
(M), F8 (F), F13 (M), F13 (F), F3 
(F), I1 (F), F6 (M), F7 (M), F11 
(F), F9 (F) 
 c. 1352A>G 0.105 p.His451Arg 25 I2 (M), F9 (F) 
COL4A4 c.2717-5A>T 0.040 IV 30 F11(F) 
 c.2501A>G 0.008 p.Lys834Arg 31 F11 (F) 
 c. 4207T>C 0.355 p.Ser1403Pro 32 F2 (F), F3 (F), I1 (F), I2 (M), F5 
(M), F12 (F), F6 (M)F10 (M), F4 
(F), F12 (F), F7 (M) 
 c.3817+9G>C 0.363 IV 33 F1 (M), F10 (M), F4 (F), I3 (M), 
F7 (M), F13 (F) 
 c.3979G>A 0.363 p.Val1327Met 11 F1 (M), F10 (M), F4 (F), F12 (F), 
I3 (M), F7 (M), F13 (F) 
 c 1444C>T 0.435 p.Pro482Ser 24 F2 (F), F10 (M), I1 (F), I2 (M), 
F12 (F), F7 (M) F1 (M), F3 (F), F5 
(M), F12 (F), F6 (M), F13 (F), F11 
(F) 
 c.3011C>T 0.444 p.Pro1004Leu 24 F2 (F), F3 (F), F10 (M), I1 (F), I2 
(M), F5 (M), F12 (F), F6 (M), F7 
(M), F1 (M), F4 (F), F12 (F), I3 
(M), F13 (M), F13 (F) 
 c.2996G>A* 0.008 p.Gly999Glu 34 F4 (F) 
 c.4394G>A** 
 
p.Gly1465Asp 11 F3(F) 
COL4A5 c.2768-
11A>G 
0,065 IV 35 F3 (F), I1 (F), F10 (M), I2 (M), I3 
(M) 
Table 2. List of the identified polymorphisms in the investigated non AS/FBH cohort. 
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minor allele frequency;; IV: intronic variant; F: female; M: male) 
* variant effect remained uncertain since we have found it in a control person (age 13 with 
two negative urinal samples, but we could not rule out later manifestation of FBH). 
** this is a rare genetic variant with uncertain consequences. It was published both as 
polymorphism and as pathogenic mutation. In Family 3 this variant is co-segregating with a 
known pathogenic mutation (c.2320G>C), so we can not elaborate on the consequence of this 
variant when it is occurring separately.  
The available medical records and the predictive clinical and pathological results are often 
incomplete or not conclusive enough to distinguish between TBMN and the different types of 
Alport (ARAS, XR), especially in not so-large families (see Table 1 and Figure 9.) Therefore, 
we decided to do sequencing-based genetic analysis on the Hungarian AS/TBMN cohort using 
our AmpliSeq panel. Selection criteria for individuals for the initial NGS analysis were as 
detailed in Methods. Then, as results of NGS analysis all the identified unique 37 genetic 
alterations were compared to data of publicly available databases such as LOVD, dbSNP, 
HGMD and Alport database (University of Utah). We identified the 21 published, previously 
mentioned polymorphisms (Table 2) and 4 published mutations (2 in COL4A4 and 2 in 
COL4A5 genes). All the four published mutations were validated in the appropriate AS/TBMN 
cases, where we confirmed that only affected individuals carried them. The 14 remaining 
alterations were investigated among AS/TBMN family members. We have classified all of 
these alterations as new mutations (5 in COL4A3 gene; 3 in COL4A4 and 6 in COL4A5 genes) 
as their exclusive presence was confirmed in the affected family members by Sanger 
sequencing (see individual family trees in Supplements). Six out of the thirteen SNP mutations 
were amino acid change (missense mutations), while the remaining seven SNP mutations were 
found in the splice recognition sites (splice variants). We also identified a COL4A4 mutation 
affecting part of exon 20 and 2 bases in the splice donor site that is a 52 bp deletion shortening 
the exon and altering splicing (Table 3).  
 
 
 
 
 28 
 
Gene Variant Consequence Family/Individual Published in 
COL4A3 c.687G>A splice region F4(F) this paper 
 c.3490G>T p.Gly1164Cys F4(F) this paper 
 c.765+2T>C splice donor F12(F) this paper 
 c.3410G>A p.Gly1137Asp F13(M) this paper 
 c.765G>T splice region F2(F) this paper 
COL4A4 c.2320G>C p.Gly774Arg F3(F) 36 
 c.2986G>A p.Gly996Arg I3(F) this paper 
 c.1100-2A>C splice 
acceptor 
F8(F) this paper 
 c.1320_1369+2del deletion, 
splice donor 
F3 (F) this paper 
COL4A5 c.1780-1G>T splice 
acceptor 
F9(F) this paper 
 c.1871G>A p.Gly624Asp F10(M), F14(F), 
I2(M) 
36 
 c.1033-6A>G presumed 
splice variant 
F7(M) this paper 
 c.2395+1G>A splice donor F5(M) this paper 
 c.1094G>A p.Gly365Glu F1(M) 37 
 c.2741G>A p.Gly914Asp F6(M) this paper 
 c.82G>T p.Ala28Ser/ 
splice 
acceptor 
F11(F) this paper 
 c.1010G>T p.Gly337Val I1(M) this paper 
Table 3. List of the identified mutations in our Hungarian AS/FBH cohort 
 
(F: female; M: male) 
To demonstrate the ease and usefulness of our methodology, we categorized all of the 14 
families as follows: F1, F5-7, F9-11 and F14 have X-linked recessive AS (XR); F3 and F4 have 
autosomal recessive AS (ARAS); F2, F8, F12 and F13 have TBMN (see Figure 1A-C). We had 
no information about additional family members in the individual (I1-I3) cases, but using our 
genetic diagnostic approach we could categorize them as X-linked recessive AS (I1 and I2) and 
TBMN (I3). 
 29 
 
 
 
 
 
 
 30 
 
 
Figure 9. Pedigree of investigated AS/TBMN Hungarian families. A, Families with X-linked 
recessive AS (XR). B, Families with autosome recessive AS (ARAS). C, Families with 
TBMN.  
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Open squares indicate males and open circles indicate females. An oblique bar indicates a 
deceased individual. White symbols indicate individuals without clinical sings of the 
AS/TBMN disease. Filled black symbols denote individuals with hematuria and/or proteinuria, 
hypoacusis or renal failure. The segment shaded circles and squares indicate carriers for a 
Chromosome 2 (COL4A3 or COL4A4) mutation. A circle that has a dot inside indicates a 
COL4A5 mutation carrier. The plus signs indicate the index patients whose DNA was analysed 
by NGS. The identified mutation(s) for each family is shown. 
 
IV.2. Clinical exom sequencing of ECD associated genes. 
 
Family I. 
One missense variant in FGF10 gene (c.620A>C; p. His207Pro) was identified in the sample 
of the affected boy by NGS (Figure 10). 
Figure 10. The found c.620A>C mutation in FGF10 gene in the sample of ECD2 patient. 
 
Since, this is not a published variant we performed the segregation analysis of both the affected 
and the unaffected family members (Table 4.) 
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Individual Gene Variant 
c.620A> C 
Consequence Status 
(unaffected, 
carrier, 
ECD) 
ECD2 FGF10 c.[=]+[620A> C] p. [=]+[His207Pro] LADD 
ECD3 FGF10 c.[=]+[=] p. [=]+[=] normal 
ECD4 FGF10 c.[=]+[620A> C] p. [=]+[His207Pro] LADD 
ECD5 FGF10 c.[=]+[=] p. [=]+[=] normal 
ECD7 FGF10 c.[=]+[620A> C] p. [=]+[His207Pro] LADD 
ECD8 FGF10 c.[=]+[=] p. [=]+[=] normal 
Table 4: Segregation analysis of Family I. 
 
Family II.: 
 
In the affected boy’s sample after the CES analysis we found an alteration in both the WNT10A 
(c.321C> A; p. Cys107Ter) (Fig. 11.) and in the EDA (c.752T> G; p. Val251Gly) genes (Fig. 
12.).  
 
Figure 11. The identified c.321C>A mutation in the WNT10A gene. 
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Figure 12: The identified c.752T>G mutation in the EDA gene. 
 
The WNT10A mutation is a known pathogenic variant which causes the abnormal development 
of the teeth 38. 
The EDA variant has not been published, yet. So we investigated its segregation in the family.  
 
 
Individual 
Gene 
 
Variants in the 
family 
EDA 752T> G,  
WNT10A c. 
321 C>T 
Consequence STATUS  
ECD14 EDA c.[752 G] p.[Val251Gly] XL-HED  
ECD19 EDA c.[=]+[752 T> 
G] 
p. [=]+[Val251Gly] XL-HED  
ECD20 EDA c.[752 T] p. [=]  normal 
genotype 
 
ECD21 EDA c.[=]+[752 T> 
G] 
p. [=]+[Val251Gly] XL-HED  
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ECD22 EDA c.[752 T] p. [=] normal 
genotype 
 
ECD14 WNT10A  c.[=]+[321 C> 
A] 
p. [=] +[Cys107Ter] OODD  
ECD19 WNT10A  c.[=]+[321 C> 
A] 
p. [=] +[Cys107Ter] OODD  
ECD20 WNT10A  c.[=]+[=] p. [=]+[=] normal 
genotype 
 
ECD21 WNT10A  c.[=]+[321 C> 
A] 
p. [=] +[Cys107Ter] OODD  
ECD22 WNT10A  c.[=]+[321 C> 
A] 
p. [=] +[Cys107Ter] OODD  
Table 5: Segregation analysis of Family II. 
 
Family III. 
After the evaluation the affected boy’s CES result we found a not-published, homozygous, 
presumably pathogenic missense variant (c.173G>A; p.Arg58His) in KRT 74 gene (Fig.13.). 
 
Figure 13: KRT74 mutation in the sample of the affected boy. 
 
By the segregation analysis (Table 6) we proved that this 2 mutation were inherited from both 
parents.   
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Individual Gene 
 
Variant 
c. 173G>A 
Consequence STATUS 
ECD/29 KRT74 c. [173 G>A]+[173 
G>A] 
p.[Arg58His] + 
[Arg58His]  
Hair/nail 
type ED 
ECD/30 KRT74 c.[=]+ [173 G>A] p.[=]+[Arg58His] carrier 
ECD/31 KRT74 c.[=]+ [173 G>A] p.[=]+[Arg58His] carrier 
Table 6.  Segregation analysis of Family III. 
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V. Discussion 
 
V.1. Alport related disorders 
 
AS and FBH are inherited renal diseases, with an incidence rate of 1:50,000 in case of 
AS and around 1:200 in case of FBH 36,39. Type IV collagen is an important structural protein 
in basement membranes, has a triple helical structure, which consists of a Col4A3, a Col4A4 
and a Col4A5 protein 40. Since COL4A3 and COL4A4 genes are coded in an autosomal 
chromosome, a single mutation in any of these two genes only leads to FBH in both sexes, as 
half of the triple helix has normal structure. However, a single mutation in X chromosome 
coded Col4A5 protein will lead to AS in males (disrupting all forming triple helix) and varying, 
intermediate phenotype in females. Genetically FBH is a special carrier form of AS since it also 
causes phenotype (not like in classical recessive metabolic diseases such as PKU) and 
traditionally treated as independent disease. Successful identification of genetic mutation in any 
of these 3 COL4A genes - even before the clinical signs can be observed - could provide an 
early differential diagnosis for FBH/Alport patients. 
We established a new, amplicon based NGS method which has three advantages: 1, it is 
reliable, cheaper (less than 500 euro per sample) and faster than the traditionally used Sanger 
capillary sequencing, 2, can provide DNA sequence information from all three COL4A genes 
simultaneously and 3, has the potential to detect single nucleotide polymorphisms (SNPs) and 
various sizes of insertions/deletions as well. Using our NGS panel and the approach outlined in 
this thesis we successfully identified causative mutations in all investigated AS/FBH instances. 
In our study 37 genetic variations were identified from which there are 14 unpublished 
and 3 published mutations, thus causative mutations were successfully identified in all 
investigated cases. Out of our 17 cases 10 (as was expected) were X-linked AS (caused by 8 
different COL4A5 mutations), we had 5 FBH cases (3 with three different COL4A3 and 2 with 
two different COL4A4 mutations). In case of Family 4 we have identified two COL4A3 
mutations, while in Family 3 we have identified two COL4A4 mutations causing autosomal AS 
in both cases. In our cohort we not only detected non-synonymous (amino acid change) SNPs 
and splice mutations, nine and seven respectively, there was also a 52 bp deletion revealed. 
Eight amino acid changes caused Glycine substitution in collagenous domains, what is a well-
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known pathogenic alteration in Col4A proteins. Interestingly, a missense mutation (c.82G>T; 
p. Ala28Ser mutation in family 11, which also alters a conserved base of the splice acceptor 
site) was detected in a non-collagenous domain of Col4a5, which segregation was coherent with 
the observed clinical symptoms in the family. In two other cases the splice regions within exons, 
in two cases splice donor sites, while in 3 cases splice acceptor sites were affected. There was 
a COL4A5 splice site mutation variant which is outside the usual +/- 1-2 splice donor/acceptor 
site (c.1033-6G>A in Family 7), that although fulfilled all of our mutation classification criteria 
(detailed in Supplement 1.) without additional functional test we only presumed that it is 
pathogenic. 
Up to now there are less than 1000 classified causative variants in public databases 
(HGMD, dbSNP, ClinVar) regarding the three COL4A genes causing AS/FBH which are 
around 4% of the whole exonic target region. The vast majority of the published mutations 
coming from X-linked COL4A5 data, even if either of the two autosomal COL4A genes is longer 
and their mutations can cause not only the more frequent FBH but also AS as well. One of the 
possible explanations could be that lots of FBH cases (caused by a single mutation either of 
COL4A3 or COL4A4) remain undiagnosed. With the introduction of simultaneous sequencing 
of all three COL4A genes by NGS, we should expect more sequence data from COL4A3 and 
A4 in the near future. Both mutations and polymorphisms in the 3 investigated COL4A genes 
are thought to be highly population-specific (due to non-existing selection pressure in case of 
the polymorphisms and only low selection pressure in case of FBH). But, to our surprise, none 
of the 21 identified genetic variations in our control group proved to be unpublished and 
Hungarian population specific. In scientific literature an autosomal dominant (AD) form of AS 
is also mentioned. Most of the autosomal dominant AS data comes from an era where the 
technical limit (error rates) of sequencing was comparable to the claimed frequency (around 
1%) of this form of AS. However, a recent paper using NGS claims that there was an astonishing 
portion of autosomal dominant AS (31%) of their solved cases 10. In the light of these data we 
should expect to find around 5 AD AS among our 17 cases, but we have not found any.  
In our opinion there is a widespread confusion in the clinical and pathological 
terminologies used to describe FBH, TBMN and AS. FBH is used by nephrologist as a 
descriptive term for cases when only haematuria (usually non progressive, without proteinuria 
or impaired hearing or vision) could be detected throughout the family, which is only a subset 
(although the largest) of all the TBMN cases. TBMN on the other hand is a term used by 
pathologists describing the thin basement membrane phenomenome of the kidney, which in 
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some cases result slowly progressive haematuria with proteinuria and as an age-related process 
can reach ESRD in elderly patients. In their paper Fallerini C. et al presented 7 AD AS families 
in detail with a single identified autosomal COL4A3 or A4 mutation 11. Their conclusion could 
be biased by the fact that 45% of their AS/FBH cases went without mutation identification. It 
is also worth to note that in all of their published AD AS cases ESRD presented only in older 
age (between 52-74 with an average of 63 years), without a single case with eye problem and 
with only 4 elderly cases with hearing loss. According to WHO data (updated in 2015 March) 
approximately one-third of people over 65 years of age are affected by disabling hearing loss 
which is fully agrees with their reported rate.  
Further on there is no known explanation for the biological foundation of AD AS. In 
cases where collagen triple helix formed by one (as in case of Type VII collagen, 3 identical 
chains coded by COL7A1 gene) or two different collagen chains (as in case of Type I collagen, 
consisting of two chains coded by COL1A1 and one coded by COL1A2) the dominant negative 
effect of a single autosomal mutation is known 41,42. In these cases, due to the formation of 
homodimers/homotrimers, a single mutation in an autosomal gene could lead to stronger 
phenotype than a null allele. The mutated protein will bind to the normal protein and result only 
around 25% of functional dimer (and even less in case of trimers) while autosomal null alleles 
lead to ~50% functional protein in heterozygotes. This is not the case in the forming Col4a3-4-
5 triple helix, where all three chains are different and coded by different genes, so it does not 
comply with the current biological model of negative dominant effect. FBH biologically is the 
result of reduced amount of proper Col4a3-4-5 triplex, while AS is the result of the lack of the 
functional protein. 
Based on our own observation on the genetic analysis presented here; confusing 
interpretation on age related clinical symptoms and the lacking of biological foundation we 
think that AD AS, as genetic term doesn’t exist and shouldn’t be used. We think that the alleged 
autosomal Alport cases genetically are either a single severe autosomal mutation leading to 
phenotype in between FBH/AS only in higher age (so it is a slowly evolving TBMN) or it could 
also be the result of unsuccessful genotyping of autosomal AS due to technical (for example 
the use of ineffective insertion/deletion detection algorithm) or differences in their genetic 
variation classification approach that heavily relies on prediction softwares. 
As far as we see Alport syndrome and its related diseases and their observed 
clinical/pathological heterogeneity (heamaturia, ESRD, hypoacusis, TBMN) is such a 
biological problem, which has quantitative inheritance elements. In individuals without 
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mutations in the three investigated COL4A genes has the full amount of fully functional triple-
helix. In the individuals (independently from gender) with a mutation in either COL4A3 or 
COL4A4 gene there is about half of the theoretical maximum amount of functional triple-helix. 
If there is a COL4A5 mutation in a male, than there isn’t any fully functional triple-helix formed. 
In females, since random inactivation of X chromosome occurs, approximately 50% of fully 
functional triple-helix will form, but this could be altered (positively or negatively) by the 
imbalances of X inactivation. This also could explain the variable phenotype even in a family. 
The situation in the case of extracellular basal membrane is even more complex, since the 
observed clinical phenotype does not depend on a single cell genotype rather from the genotype 
ratio within Type IV collagen producing cell population. The other sources of the heterogeneity 
naturally are the mutations causing different level of malfunction in the forming triple-helix. 
This phenotypic variability leads to introduce the term semi-dominant inheritance, which has 
an intermediate phenotype different from both dominant (since the phenotype of a heterozygote 
is not the same as a homozygote mutant) or recessive (since the phenotype of a heterozygote is 
not the same as a homozygote normal). As a result of this we can view Alport and its related 
diseases as a spectrum disorder, where the biological base of the different phenotypes is the 
amount of fully functional (or impaired/null) Type IV collagen formed. The two extremities of 
this spectrum are FBH with only mild, non-progressing haematuria, while the other end is 
Alport syndrome with serious kidney, eye and hearing phenotype. 
Because the prognosis of FBH and AS is entirely different while the early symptoms 
could be similar, both the genetic classification and the above mentioned distinction in our view 
is extremely important. By providing correct genetic data and by establishing the correct 
inheritance pattern within family, it could help both clinicians and genetic counsellors 1) to 
communicate and make an early, informed decision about the possible speed and direction of 
the progression in the family, 2) to establish the circle of the family members who need regular 
checking, 3) to select a possible kidney donor within the family and 4) support positive family 
planning. The genetic test could lead to the earliest diagnosis even before the manifestation of 
clinical symptoms that would be a big benefit for patients, for their families and for the health 
systems as well. For patients with some of the earlier clinical symptoms or even before, genetic 
diagnosis could mean preventive treatment such as using ACE inhibitors which could delay the 
onset of end-stage renal failure and improve life expectancy, even when begun before the onset 
of proteinuria 5,6,30. For family members the biggest benefit could be the possibility for positive 
family planning, and the awareness of possible kidney problems. And for the health system the 
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cheap genetic diagnostic procedure eliminates the need for long and uncertain clinical staying, 
and lots of unnecessary, less conclusive and much more expensive tests and examinations. The 
best tool for this job is the DNA-based molecular genetic analysis of the proband and his/her 
relatives. Using peripheral blood as DNA source for genetic analysis causes much less trauma 
for patient (especially children) compared to the kidney biopsy, which carries certain level risk 
of severe complications31. The result of the DNA sequencing is independent of the age of the 
proband, from the stage of the disease and in most cases provides quick and accurate 
confirmation of the diagnosis. It can be also performed on a single person independently when 
the family history is not available. Furthermore, in cases where no detailed clinical and 
pathological data is available genetic analysis could be the first choice. 
V.2. Ectodermal dysplasia related disorders 
There are more than 150 types of Ectodermal dysplasia described so far, with a 
combined incidence of 7/10000. Every organs (skin, skin appendages, hair, teeth, eccrine-
glands) and tissues which are developing from the embryonic ectoderm can be affected. More 
than 150 types of ECD were described coded by more than 140 genes. Due to the large number 
of the affected genes it was nearly impossible to confirm the clinical diagnoses by genetic 
analysis in every cases. To diagnose ECD we choose the CES sequencing approach, where we 
can investigate all the known pathogenic ECD genes at the same time. In my thesis I show the 
genetic analysis of three ECD patients and their families by CES and Sanger sequencing.  
In the first family we found a FGF10 (fibroblast growth factor 10) gene (c.620A> C) 
mutation. The encoded protein is part of a family of proteins which take part in important 
processes during the early embryonal development (such as cell division, regulation of cell 
growth/maturation, wound healing, the lacrimal system, the ears, the salivary glands (saliva 
glands in mouth, teeth etc.). We validated the presence in the proband by Sanger sequencing. 
This mutations was not published in the literature for this we performed the segregation analysis 
in the family. The segregation analysis (Table 4) shows that only the affected family members 
have the mutant variant, the unaffected family members carry the wild type variant. The clinical 
phenotype agree the symptoms which were described in OMIM caused by mutations in FGF10 
gene. Mutations in FGF10 gene known to cause the lacrimo-auriculo-dento-digital (LADD) 
syndrome 43 with autosomal dominant inheritance therefore based on the detailed clinical -, 
genetic analysis and our variant assertion criteria we confirmed the LADD type of ED in this 
family.  
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In Family II. we found two missense mutations in two different genes. One is in the 
WNT10A gene (c.321C> A; p. Cys107Ter) and another one in the EDA gene (c.752T> G; 
p.Val251Gly). The identified WNT10 mutation is a known pathogenic, which was published 
by Axel Bohrin et. al38 
Mutations in WNT10A gene know to be responsible for tooth malformations and plays role in 
another ED type, Odontoonychodermal dysplasia (OODD). Fadhil et al. first described 
phenotype related WNT10A mutation and the first demonstrated, that altered WNT signalling 
pathway could contribute to ectodermal dysplasia (OODD)44. However in randomly 
investigated samples with tooth agenesis only 40% had at least one mutation in the WNT10A 
gene 45,46 Phenotype of family II. agrees with this findings. The affected boy’s nephew whose 
got only WNT10A mutation has only Odontoonychodermal dysplasia. Based on the segregation 
analysis and the phenotype we confirmed the OODD type of ED in ECD14, ECD19, ECD20, 
ECD22. The identified novel EDA mutation was not described in the literature so we had to 
confirm the pathogen status. EDA gene encode the Ectodysplasin-A transmembrane protein 
which consist of 391 amino acids coded by 8 exons. The 6th exon codes 18 amino-acids (247-
265) which is part of the extracellular domain of the protein UniProt database). This mutation 
is likely to affect that part of the extracellular EDA which can interact with EDA-receptor 
(EADR). This interaction is responsible for initialisation of the proper differentiation of the 
sweat glands. 
In view of this and the segregation analysis (only the affected members have the mutant gene) 
we concluded that the identified novel EDA mutation and the published causative WNT10A 
mutation was responsible for the mixed phenotypes in this family. The affected boy, his mother, 
his grandmother and his sister have both Hypohidrotic ectodermal dysplasia and OODD. The 
proband’s sister has 3 children. Two of them have only tooth agenesis and have normal sweating 
abilities. We confirmed his clinical status by genetic analysis. He only inherited the WNT10A 
mutation which responsible for OODD. 
In Family III. we found a KRT74 gene variant both in homozygous and in heterozygous 
(carrier) forms. KRT74 belongs to the family of type II keratins that are specifically expressed 
in the inner root sheath of hair follicles and in nail matrix and its mutations known to cause 
ectodermal dysplasia type 7 47–49 . The identified mutation in KRT74 is in the first exon at c. 
173G>A which causing Arg to His amino-acid change at the position of 58. The investigated 
boy is carrying this mutation in homozygous form, while both of his parents are carrying this 
mutation in heterozygote fashion which is an agreement with the inheritance mode of this 
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disease (autosomal recessive). To date, according to our knowledge, the medical relevance of 
this variant is not described elsewhere.  
Up to now there has not been any cure for ECD. However, recently researchers 
developed a new therapy for X-linked Hypohidrotic form of ED (XLHED) called EDI200 50. 
Treatment of pregnant mother with EDI200 or of the newborn baby shortly after birth leads to 
the normal phenotype (normal working hair follicules and sweat glands)50. To start the therapy 
in time the early genetic diagnosis which confirms is crucial. To exclude other genes which 
cause likely XLHED phenotype (EDAR, EDARADD, etc.) not enough to investigate only the 
EDA gene. We need to investigate all ECD related genes. To meet these requirements, we think 
that CES could be a reliable and economical choice. In addition the simultaneous investigation 
of all ECD related genes open the door to the further development gene specific therapies50. 
Besides the mentioned three cases we investigated other 5 families affected with different types 
of ECD. To diagnose the complex diseases is a big challenge to both the clinicians and to the 
diagnostic laboratories. Earlier, we made genetic tests to confirm the co-segregation pattern of 
haematuria with STR markers and LOD score analysis and we performed mutation screening 
with High Resolution Melting (HRM) analysis and Sanger sequencing of a different set of 
complex diseases. However this approach was not successful to identify the causative mutations 
in many cases. In cases where more than a single gene is responsible for the disease, we need 
diagnostic tools that can simultaneously investigate all the associated genes. In this study I first 
presented cases with Alport syndrome and its related diseases where we developed a custom 
targeted NGS panel capable to detect genetic variations in all three COL4A genes 
simultaneously. In the second part of my thesis I presented three cases with clinical diagnoses 
of ECD, where we used a commercially available CES kit (TruSight One, Illumina) in order to 
identify causative mutations in any of the 141 known ECD-causing genes.  
The combined use of NGS data and targeted validation and segregation analysis of the 
mutations in the analysed cohort proved to be a suitable strategy for the assessment of correct 
genetic diagnosis in complex diseases 
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Supplement 1. 
 
Genetic Diagnostic Laboratory 
Assertion Criteria 
For variant description we follow the recommendations of the Human Genome Variation 
Society (Nomenclature for the description of sequence variants ). For variant classification 
we follow the guidelines of the ACMG Laboratory Practice Committee Working Group 
(Richards et al 2008. Gen in Med. 10: 294-300 ). 
Sequencing variants are classified in one of five categories. Below is a summary of the 
guidelines used by our laboratory (as of 1/1/2016) 
 
For clinical whole exome or targeted (re)sequencing, variants classified as pathogenic variants 
will be confirmed by Sanger sequencing.  
1. Pathogenic For a variant to be classified as a pathogenic variant it must be located in a 
gene known to be responsible for disease and the phenotype of the patient being tested 
is consistent with that disease. 
a. Variants predicted to result in the loss of protein function (may or may not have 
been previously reported in patients with disease) 
1. frameshift (an insertion or deletion that is not a multiple of 3 nucleotides) 
2. nonsense (introduction of a premature stop codon) 
3. splice junction (at positions +1,+2, -1 and -2  in an intron) 
4. change in an initiation codon 
5. change in the termination codon 
b. Variants predicted to result in an amino acid replacement (missense) with one 
of the following conditions met: 
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1. variant demonstrated to result in reduced protein function (loss of 
function), or aberrant protein function (gain of function) in an 
appropriate functional assay 
2. common disease causing pathogenic variant in a specific population 
based on evidence in the literature 
3. variant reported in multiple affected individuals and demonstrated to 
segregate with disease in at least a single family 
c. Variants demonstrated to result in aberrant splicing in an appropriate functional 
assay (eg. intronic or silent) 
 
2. Likely Pathogenic 
a. Recessive conditions: (all the following conditions must be met) 
1. diagnosis has been confirmed by biochemical testing or patient 
phenotype is specific for disease 
2. variant located on opposite chromosome from a known disease causing 
pathogenic or likely pathogenic variant 
3. variant occurs at an evolutionarily conserved nucleotide and/or amino 
acid 
4. variant not present in dbSNP, EVS (Exome Variant Server) or other 
publicly available database at a frequency consistent with being a benign 
variant 
b. Dominant conditions: (all of the following conditions must be met) 
1. variant segregates with phenotype in the family being tested or 
2. testing parental samples demonstrates that the variant occurred de novo 
3. variant not present in dbSNP, EVS (Exome Variant Server) or other 
publicly available database at a frequency consistent with being a benign 
variant 
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3. Benign variant (one of the following conditions must be met)* 
a. Variant reported in dbSNP, EVS, locus specific databases or EGL database at a 
population frequency higher than expected given the prevalence of the disease 
and mode of inheritance. 
b. Variant reported in a control population at a frequency inconsistent with being 
causative of disease 
c. Other evidence from published literature that indicates the variant has no effect 
on function 
*Benign variants are interpreted as described above and not reported in clinical reports. A list 
of these variants is available upon request. 
4. Likely benign variant (one of the following conditions must be met) 
a. Variant found heterozygous (for dominant) or homozygous (for recessive) in 
multiple unaffected individuals. 
b. Variant found in cis with a pathogenic variant in multiple unrelated individuals 
c. Variant found in an unaffected family member (for dominant) 
 
5. Variant of unknown clinical significance (VOUS) 
If a variant is in a gene that is not consistent with the patient's phenotype, it will be reported as 
a variant of unknown significance and additional clinical information may be needed. Variants 
that are identified in genes not known to cause disease will be also classified as variants of 
unknown significance. 
 (if unable to classify the variant in one of the four categories above, it will be classified as 
a VOUS) 
a. Variant not reported in HGMD, locus specific databases, published literature, 
dbSNP or EVS 
b. Variant reported in dbSNP or EVS, but at an allele frequency insufficient to rule 
out clinical significance based on mode of inheritance and severity of disorder 
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c. Variant reported in a single individual with insufficient segregation and/or 
functional data 
d. Variant reported in a single individual with inadequate clinical information 
Note: In the presence of conflicting data the term variant of uncertain significance 
may be used. 
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